Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The APSantiCo Observational Study - Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination

NCT05313048 is registered in ClinicalTrials.gov with Cardioangiologisches Centrum Bethanien as lead sponsor.

NCT NCT05313048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05313048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The APSantiCo Observational Study - Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination
Lead sponsor
Cardioangiologisches Centrum Bethanien
Phase
Observational
Overall status
Completed
Start date
March 15, 2022
Completion date
October 24, 2022
Enrollment
82 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antiphospholipid syndrome, covid-19 infection, covid-19 vaccination